Trading Summary - December 27. Another satisfactory

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
177
Trading Summary - December 27.

Another satisfactory status quo day for $DIGX whilst we await start of 2018.

This suits the main repeat traders who are already loaded at .0003 + .0004 as they will not incur 33% tax on profits (for the first few runs anyway) when $DIGX gets run up in due course.

2.1M bought on the bid at .0003 from insignificant paint downs and / or very small holders.

210M bought at .0003 since August 23 - the majority by longs building an inventory of shares to be traded on the several runs that are likely to come in 2018.

All followers of $DIGX here have no excuse for not being set up for 2018 now. There has been ample opportunity to load a combination of .0003s and .0004s for 18 weeks - with .0004s being the only realistic option left now for any significant amount.

Anyone who wants .0004s - because the likelihood of getting any meaningful quantity of .0003s is limited in the 2 remaining trading days in 2017 - better not wait too long. Once we get into the new tax year, the .0004s could get taken out in seconds / minutes setting off a run - just like happened to the year start ask at the beginning of 2017.

In addition, in 2017, PRs came out in both Jan and Feb.

As always, anything could happen at anytime. So stay sharp if you don't already have all the shares you need to make your profit expectations up to Q4 in March 2018 and thereafter in 2018. Prior warning and / or scanner alerts of any significant buys starting a run up will not be given on iHub but they will be alerted here immediately.

Content below the line mainly unchanged from last update - relevant to those that are new here.

The PR associated with the 2017 Q3 - that was filed on November 16 - has not been issued yet. The PR associated with 2016 Q3 came out on December 12, 2016 - see here:

http://www.otcmarkets.com/stock/DIGX/news/DIG...08&b=y

Until the PR comes out highlighting the excellent results - and hopefully also updating future brand expansion plans - only those who were looking for the Q3 - who mostly already have their shares - have seen it.

http://www.otcmarkets.com/stock/DIGX/news/DIG...08&b=y

In due course, the Q4 results will speak for themselves and - when PR'ed to the wider investing community - we should see serious additional new interest due to the low O/S and relatively high positive revenue for a stock in this price range - just as happened for the 2016 Q4 and the 2017 Q1 and Q2. In addition, those reluctant to buy on the ask whilst they think they still have a chance of filling on the bid before the Q4 will probably change their mind in January - ask buying started on January 13 at the beginning of this year.

As previously stated, the large additional share retirement of 275M shares since Jul 31 - on top of the 150M retired Dec 2016 > May 2017 making 425M total - has not been PR'ed yet either.

Excellent update recently on the Verified Company Profile share structure at otcmarkets.com from the Transfer Agent (see new sticky #1902) - this has not been PR'ed yet to the wider investing community and has not been spotted by the inattentive on iHub:

O/S and A/S confirmed unchanged as at Nov 30, 2017.

Float same as for all the runs this year - 50M reduction since Dec 2016.

Another 275M shares retired between Jul 31 and Oct 31 (as promised).

That takes total retired to 425M since May 31 - a significant reduction on such a small A/S and O/S for a stock in this price range.

The long-term whales who trade $DIGX will continue to buy shares at any price that makes sense to them to use on multiple runs during the remainder of 2017 (there is usually a Q4 estimate + plans update in December) and throughout 2018. It is already known from posted comments and observation that at least 4 of the main whales are buying shares - on the bid and on the ask - from the impatient at year end.

As predicted, at least 4 x whales who trade $DIGX continuously throughout each year were happy to take around 100M at .0003 when a few impatient people decided to trade for a loss at .0003 on December 14.

The big boys in DIGX now probably already have an inventory of 50M>200M each for trading through to end-2017 and up to the 2017 Q4 in March 2018.

Any shares bought at .0004 will be worth an easy 150%+ profit on any of numerous runs likely to happen through to Q4. Shares bought at .0005 should easily return 100%+ at some point in 2018.

In my experience, 70M>100M (or 250M at year end for the next year) is the optimum amount to take best advantage of each run whilst keeping the 25M cheapest batches for the bigger runs next year (especially Q4 in March 2018 when the full year profits will be up). My cheapest 25M retained for next year highs will not require any shares bought above .0003 now so all others will be tradeable going forward.

As expected, the status quo has been pretty much maintained throughout the inter Q2/Q3 PR period with it making little difference to long-term traders whether shares are picked up at .0003/4/5/6 - they will see a profit on all of them by Q4 and on various runs between.

We can now look forward to additional updates on both the possible merger discussed recently and the implementation of the additional services being offered in the chiropractic chain offices - per the Strategic Growth Plan announced earlier - over the coming days, weeks and months..

$DIGX will most likely not be allowed to go to previous year-end or inter-Q lows.

In my opinion, nobody has bought $DIGX in 2017 at a price that it isn't likely to exceed in the coming months (2017 high .0013) through to the Annual Report (March 2018).

Ludicrous claims by the notorious bashers currently on iHub - "RFB", "munimi", "Crown Capital" and "surfkast" - are clearly seen as such by all serious traders and now even by most short term (next Q) iHubbers.

Debunking nonsense posted by morons on iHub, there is absolutely no need or intention to do a reverse split. The share structure is exceptionally thin - with no dilution - and the company has been buying back shares. OTC market specialists who trade $DIGX continuously would not be loading 50M>200M shares at these end-2017 prices to trade over the next 12 months if there was even the remote possibility of a reverse split.

There have never been any promotion campaigns on $DIGX in the modern era on the current business model - since the acquisition of Expressions Chiropractic & Rehab in January 2016 and I don't think there will be any. The PRs alone + OTC market off-the-bottom specialists spotting the loading on scanners, keeping accurate records and networking with other traders has proved sufficient to generate multiple runs in 2017 and should do the same in future throughout 2018.

Regardless of whether iHub posters lose interest over the coming days and weeks, detailed coverage will continue here as $DIGX remains one of my top picks for repeat profits for those that are patient and trade it to best effect (keep all cheapest batches of shares - create an inventory of shares at higher prices to trade on every run - big or small). It remains the top earner in 2017.

In addition, money is not considered "dead" by the most successful traders in the OTC market when they know it will provide a significant return further down the line because they are in a position to understand and influence - through keen observation and record keeping - what volume of shares is likely to be made available for purchase at any particular level.












American EcoFuels Inc (AEFI) Stock Research Links

AEFI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thesis Elements Expands Portfolio with Mappify Buy

Updated Category News Views 32

Mappify Acquisition: A Smooth Move for Higher Ed Picture a college student trying to juggle classes, work, and life like it's a circus act. That's not too far off from reality, and it's where Thesis America and its new acquisition, Mappify, come into play. By scooping up Mappify, Thesis aims to untangle this scheduling chaos for students across the board. From Data to...

Continue Reading
iHeartMedia Faces Investigation; Shares Plummet 60%

Updated Category News Views 5

A Sudden Pivot Leaves Shareholders Reeling Nothing like a company blindsiding its investors amid the bustling market chaos. Welcome to the iHeartMedia saga, where promises of profit have turned into a bitter pill for shareholders. On November 9, 2026, the radio giant pulled a fast one by drastically revising its full-year Adjusted EBITDA forecast down to $550...

Continue Reading
Supermetrics Debuts AI Campaign Manager for Marketers

Updated Category News Views 88

These days, digital marketing feels like trying to build a puzzle in a sandstorm. You've got all these pieces flying around, valuable insights buried somewhere in the mix, and you can't just toss 'em together however you like. Supermetrics steps into this whirlwind with their new tool, Campaign Manager, promising marketers a direct line from insight to action. Finally, a...

Continue Reading
Jumptuit's AI Patent Promises Health Alerts Innovation

Updated Category News Views 85

Jumptuit's Patent: A Game-Changer in Health Tech Alright, strap in—Jumptuit just nabbed a patent that might flip the script on how we think about environmental health risks. The U.S. Patent and Trademark Office finally gave Donald Leka and his brainchild, Jumptuit, the green light on something they're calling 'AI Systems and Methods for Environmental Exposure and Early...

Continue Reading
Biozen Slashes BP Measurement Time by 40%, No Sacrifice

Updated Category News Views 41

Biozen's Bold Leap in Blood Pressure Measurement You think blood pressure measurement, you think inconvenience—right? Not so fast. Biozen's got something up their sleeve that's shifting the game. At the latest American Heart Association's Scientific Sessions in Chicago, Biozen's bigwigs whipped out their new tech: the BP2000. This isn't just any update; it's a 40% cut...

Continue Reading
Broadridge's Dividend Move: A Steady Signal

Updated Category News Views 133

Broadridge Puts a Cherry on Top with Dividend Declaration Ah, dividends—the bread and butter for those of us who savor the small victories that come with holding onto our stocks. Broadridge Financial Solutions, Inc. (NYSE: BR) just dangled a juicy carrot in front of its shareholders with their freshly declared quarterly cash dividend of $1.09 per share. Now, I've been...

Continue Reading
Nevada Organic Phosphate Cancels Share Consolidation Plan

Updated Category News Views 42

Unexpected Turn for Nevada Organic Phosphate In an abrupt twist that surprised some investors, Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) (FSE: ZV8), the Canadian trailblazer in organic phosphate mining, called off its proposed share consolidation. Dropping the plan wasn't just a stroke of luck; it came after hearing the grumblings of shareholders concerned...

Continue Reading
2027 Bass Legends Honored: NAMM Awards Spotlight

Updated Category News Views 73

A Celebration of Low-End Legends When it comes to those deep, booming riffs that make your spine tingle, the bass guitar holds a special place in the world of music. And at the 2027 Bass Magazine Awards, this unsung hero of countless tracks is getting its due recognition. Folks, we're talking about a star-studded lineup of bass legends who’ve turned the world of music...

Continue Reading
Grandparents' Holiday Gift Picks: Expertly Tested Ideas

Updated Category News Views 43

Hunting for the Perfect Gift? Look No Further The holiday hustle and bustle inevitably sparks one of the annual dilemmas: What on earth should you buy those grandkids of yours? No need to get all twisted up this season. Enter ZestYears, the savvy go-to guide for grandparents who want to nail gift-giving without breaking a sweat or the bank. These folks, based out of...

Continue Reading
Pyxus Starts Exchange Offer for 8.50% Notes, 2027

Updated Category News Views 70

Pyxus Restructures Via Exchange Offer Pites, it's time for Pyxus International to show its hand. The global agricultural player has rolled up its sleeves, kicking off an exchange offer for its 8.50% notes maturing in 2027. With $148.3 million hanging in the balance, this move is their shot at managing debt and keeping things steady—like a farmer making sure the...

Continue Reading

Top 5 Most Recently Viewed Articles

Comarch Recognized as Leader in European e-Invoicing Market

Updated Category News Views 57

Comarch Achieves Recognition in European e-Invoicing Comarch has been named a Leader in the IDC MarketScape 2024 European Compliant e-Invoicing Vendor Assessment. This recognition highlights the company’s excellence in delivering exceptional e-invoicing solutions tailored for compliance across various European markets. Innovative Solutions by Comarch The IDC report...

Continue Reading
Imperial Metals Experiences Significant Growth in Q3 Results

Updated Category News Views 75

Imperial Metals Reports Strong Financial Performance for Q3 2024 Imperial Metals Corporation (TSX:III) has released its financial results for the third quarter of 2024, revealing impressive growth metrics that highlight the company's resilience and operational efficiency. Financial Highlights In the third quarter, Imperial Metals reported an adjusted EBITDA of $74.2...

Continue Reading
Cimplifi Gains Recognition for Excellence in AI Solutions

Updated Category News Views 212

Cimplifi Earns Relativity Solution Competencies Recently, Cimplifi, a front-runner in integrated eDiscovery services, made headlines with its remarkable achievement of securing two new solution competencies from Relativity. These include the Relativity aiR for Review competency and the Relativity aiR for Privilege competency. This recognition underlines Cimplifi's...

Continue Reading
Upcoming Subsea 7 S.A. Conference Call on Q3 2025 Results

Updated Category News Views 218

Subsea 7 S.A. Announcement for Third Quarter Results Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) is set to release its third quarter results for the year 2025. This significant financial report will cover the period that concluded on 30 September 2025, and the company plans to make it available on Thursday 20 November 2025 at 08:00 CET. Details of the Earnings Call...

Continue Reading
Japan's Approval of New Urothelial Cancer Treatment Brings Hope

Updated Category News Views 112

Japan's Major Medical Milestone for Cancer Treatment Astellas Pharma Inc. has recently made headlines with a significant milestone in cancer treatment: the approval of PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) by Japan's Ministry of Health, Labour and Welfare (MHLW). This groundbreaking decision marks the first official approval of a...

Continue Reading